Last reviewed · How we verify

Innostellar Biotherapeutics Co.,Ltd — Portfolio Competitive Intelligence Brief

Innostellar Biotherapeutics Co.,Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 1 shared drug class
  2. Genentech, Inc. · 1 shared drug class
  3. Genzyme, a Sanofi Company · 1 shared drug class
  4. Hoffmann-La Roche · 1 shared drug class
  5. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. Seoul National University Bundang Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Innostellar Biotherapeutics Co.,Ltd:

Cite this brief

Drug Landscape (2026). Innostellar Biotherapeutics Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/innostellar-biotherapeutics-co-ltd. Accessed 2026-05-18.

Related